Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year. IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $ ...

Teddy bears offer emotional comfort and connection for adults with cancer, easing anxiety and fostering trust during ...

A new leak has revealed the Galaxy S25 Edge in full, including its battery size, specs, and colors ahead of a May 13 release.

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

This fact sheet discusses cannabis health risks based on frequency of use, the form consumed, and a patient’s other therapies ...

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout ...

Podcasts > News > Boston Public Radio Podcast From WGBH Radio Join hosts Jim Braude and Margery Eagan for a smart local conversation with leaders and thinkers shaping Boston and New England. We ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Zevaskyn ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...